Dr. Harshman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana 1230
Boston, MA 02215Phone+1 617-632-4524
Education & Training
Stanford Health CareFellowship, Hematology and Medical Oncology, 2006 - 2009
Yale-New Haven Medical CenterResidency, Internal Medicine, 2003 - 2006
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2003
Certifications & Licensure
CA State Medical License 2006 - Present
FL State Medical License 2023 - 2025
MA State Medical License 2012 - 2021- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Start of enrollment: 2009 Oct 01
- Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2014 Aug 01
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Start of enrollment: 2017 Apr 28
- Join now to see all
Publications & Presentations
PubMed
- Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase...Matthew S Robertson, Yating Wang, SuChun Cheng, Hyesun Park, Shahar Glomski
La Radiologia Medica. 2024-11-20 - 3 citationsPerioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3...Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman
The Lancet. Oncology. 2024-08-01 - 1 citationsRandomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.Atish D Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M Allaire, Jaqueline Marquez
Cancer Immunology Research. 2024-06-04
Journal Articles
- Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate CancerHeather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation
- A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate CancerChristopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate
Lectures
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (E...2019 ASCO Annual Meeting - 6/1/2019
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrec...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- 13th Multidisciplinary Management of Cancers: A Case-based ApproachStanford Hospital & Clinic, Stanford, California - 3/9/2012
Press Mentions
The Combination of Pembrolizumab and Radium-223 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Atish ChouduryFebruary 26th, 2021
Activity of Cabozantinib in Advanced Non–Clear Cell Renal Cell CarcinomaMarch 15th, 2019
Cabozantinib Active Across Non-Clear Cell Kidney CancersMarch 6th, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
